Corcept Therapeutics Incorporated
CORT
$115.70
$1.721.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 256.15M | 164.90M | 202.13M | 207.64M | 194.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 256.15M | 164.90M | 202.13M | 207.64M | 194.43M |
| Cost of Revenue | 4.06M | 2.88M | 2.55M | 4.60M | 3.43M |
| Gross Profit | 252.09M | 162.02M | 199.58M | 203.04M | 191.00M |
| SG&A Expenses | 156.90M | 145.36M | 130.24M | 123.98M | 103.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.85M | 214.50M | 197.64M | 197.42M | 167.76M |
| Operating Income | 41.30M | -49.60M | 4.49M | 10.22M | 26.68M |
| Income Before Tax | 45.93M | -44.72M | 9.91M | 15.24M | 31.69M |
| Income Tax Expenses | 2.94M | -12.95M | -14.38M | -4.43M | -3.46M |
| Earnings from Continuing Operations | 42.99M | -31.76M | 24.29M | 19.67M | 35.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.99M | -31.76M | 24.29M | 19.67M | 35.15M |
| EBIT | 41.30M | -49.60M | 4.49M | 10.22M | 26.68M |
| EBITDA | 42.16M | -49.00M | 4.78M | 10.51M | 27.14M |
| EPS Basic | 0.40 | -0.30 | 0.23 | 0.19 | 0.33 |
| Normalized Basic EPS | 0.27 | -0.27 | 0.06 | 0.09 | 0.19 |
| EPS Diluted | 0.36 | -0.30 | 0.20 | 0.16 | 0.29 |
| Normalized Diluted EPS | 0.24 | -0.27 | 0.05 | 0.08 | 0.16 |
| Average Basic Shares Outstanding | 105.38M | 104.44M | 103.70M | 103.55M | 104.11M |
| Average Diluted Shares Outstanding | 118.39M | 104.44M | 119.86M | 119.44M | 120.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |